Anti-Retroviral Treatment Outcomes among Older Adults in Zomba District, Malawi

Joel Negin1*, Monique van Lettow2-3, Medson Semba4, Alexandra Martinuik3,5,6, Adrienne Chan2,3,7, Robert G. Cumming1

1 School of Public Health, University of Sydney, Sydney, Australia, 2 Dignitas International, Zomba, Malawi, 3 Dalla Lana School of Public Health, University of Toronto, Toronto, Canada, 4 Ministry of Health, Zomba, Malawi, 5 George Institute for Global Health, Sydney, Australia, 6 Sunnybrook Health Sciences Research Institute, University of Toronto, Toronto, Canada, 7 Department of Medicine, University of Toronto, St. Michael's Hospital, Toronto, Canada

Abstract

Background: There are approximately 3 million people aged 50 and older in sub-Saharan Africa who are HIV-positive. Despite this, little is known about the characteristics of older adults who are on treatment and their treatment outcomes.

Methods: A retrospective cohort analysis was performed using routinely collected data with Malawi Ministry of Health monitoring tools from facilities providing antiretroviral therapy services in Zomba district. Patients aged 25 years and older initiated on treatment from July 2005 to June 2010 were included. Differences in survival, by age group, were determined using Kaplan–Meier survival plots and Cox proportional hazards regression models.

Results: There were 10,888 patients aged 25 and older. Patients aged 50 and older (N = 1419) were more likely to be male (P < 0.0001) and located in rural areas (P = 0.003) than those aged 25–49. Crude survival estimates among those aged 50–59 were not statistically different from those aged 25–49 (P = 0.925). However, survival among those aged 60 and older (N = 345) was worse (P = 0.019) than among those 25–59. In the proportional hazards model, after controlling for sex and stage at initiation, survival in those aged 50–59 did not differ significantly from those aged 25–49 (hazard ratio 1.00 (95% CI: 0.79 to 1.27; P = 0.998)) but the hazard ratio was 1.46 (95% CI: 1.03 to 2.06; P = 0.032) for those aged 60 and older compared to those aged 25–49.

Conclusions: Treatment outcomes of those aged 50–59 are similar to those aged 25–49. A better understanding of how older adults present for and respond to treatment is critical to improving HIV services.

Introduction

There are approximately 3 million people aged 50 and older in sub-Saharan Africa who are HIV-positive, representing more than 13% of all HIV cases in the region [1]. These figures are likely to increase as the number of people on life-prolonging anti-retroviral treatment (ART) grows. Despite this, older people have been neglected in the global and regional HIV response. UNAIDS and other prominent data sources report prevalence rates of those aged 50 and older (P = 0.019) than among those 25–59. In the proportional hazards model, after controlling for sex and stage at initiation, survival in those aged 50–59 did not differ significantly from those aged 25–49 (hazard ratio 1.00 (95% CI: 0.79 to 1.27; P = 0.998)) but the hazard ratio was 1.46 (95% CI: 1.03 to 2.06; P = 0.032) for those aged 60 and older compared to those aged 25–49.

There has not however been much analysis conducted on older adults in sub-Saharan Africa [14,15]. Recently, one Ugandan and one South African study provided some of the first evidence reporting on treatment outcomes revealing elderly age status (50 and older) associated with higher mortality [16,17].

A recent study revealed that older Africans are less likely to have a good understanding of HIV, are less likely to have been tested and are less likely to be aware of treatment availability [18]. Along with this, for older adults in sub-Saharan Africa, issues of stigma, lack of access to health services, poor overall health [19] and ageist views on sexual behavior might negatively impact on the effectiveness of ART scale-up efforts.

In Malawi, a country with a 2009 HIV prevalence of 11% among those aged 15–49, analysis of 2007 UNAIDS data suggested that there are approximately 156,000 people over 50 who are living with HIV in Malawi or 16.8% of the total [1]. Furthermore, people over 50 make up 9.3% of Malawi’s population [20]. ART coverage has expanded dramatically over the past few years and, as of 2009, 72% of those who needed treatment were receiving it based on 2006 World Health Organization ART
Methods

Subjects were adults aged 25 and older at time of ART initiation residing in Zomba District in southern Malawi who accessed ART services in the district’s 23 health facilities between 1 July 2005 and 30 June 2010. The methods used in this study have been described in detail elsewhere (Chan et al 2010) [21]. In brief, a retrospective cohort analysis was performed using data collected with standard Malawi Ministry of Health (MOH) ART monitoring tools. ART provision was implemented as per MOH guidelines based on WHO clinical staging or CD4 count <250 cells ?m3 where measurement of CD4 is available. The first line ART regimen in Malawi is stavudine, lamivudine and nevirapine in fixed-dose combination. After initiation, follow-up was monthly and then, after approximately 6 months, patients were followed less often depending on assessment of adherence. In the project district, mortality was documented by trained health workers in health facilities and by reports from trained patient guardians where deaths occurred at home. Defaulters tracing was also conducted which revealed additional deaths.

Analyses in this paper only included those aged 25 and older to exclude those regarded by MDG [22] and UNGASS [23] indicators as adolescents. Age was defined as age at treatment initiation. The 23 health facilities where MOH ART provision is supported by Dignitas International were classified as urban, semi-urban or rural based on location and catchment area of facility. Analysis of conditions at initiation was based on examination at baseline of 52 HIV-related conditions detailed in WHO clinical staging including: acute ulcerative mouth infections, KapoSI's sarcoma, various types of pneumonia and weight loss to name a few. As per Malawi MOH guidelines, individuals were initiated based on characterization as being in WHO clinical stage 3 or 4 or, if characterized as Stage 1 or 2, based on low CD4 count if available. As a result, baseline CD4 counts were collected for only 47% of patients. Additionally, CD4 testing capacity was only available in urban settings with blood samples from rural patients being sent to urban facilities as needed.

Statistical analyses included Chi-square tests for categorical variables and t-tests for continuous variables to compare differences between groups. Logistic regression analyses were used for categorical outcomes including WHO clinical stage and number of conditions at initiation. Interactions between age and sex and between age and location of initiation were tested in the logistic regression analyses. Cox proportional hazard regression models were used to evaluate relationships between age, sex and status at initiation and treatment outcomes (death). CD4 count was not used for these analyses due to high number of missing values. Differences in survival time between groups of subjects by age categories and by sex were investigated using Kaplan-Meier survival plots. Data analysis was performed using SAS v.9.2.

For the Cox proportional hazards model and Kaplan-Meier survival curves, analyses excluded those whose follow-up status was characterized in the dataset as “missing” or suspected of having “defaulted.” This represented 22.7% (N = 2475) of all those aged 25 and older who had initiated in the five year period from 1 July 2005 to 30 June 2010. Based on a systematic review [24] and data from two studies in Malawi, [25,26] we estimate that approximately 41–50% of those lost to follow-up would have died within approximately two years. Analyses were run to identify differences in characteristics between those in the analyzed cohort versus those excluded.

Ethics Statement

The study analysis received approval from the National Health Sciences Research Committee of Malawi in April 2011.

Results

There were 10888 patients aged 25 and older who had initiated ART between 1 July 2005 and 30 June 2010 in the database. Of those, 6789 (62.4%) were female; 9469 (87.0%) were aged 25–49, 1074 (9.9%) were 50–59 and 345 (3.2%) were aged 60 and older. The older age groups had significantly (P<0.0001) higher percentages of male patients than the younger age groups: 44.9% of those 50 years and older were male compared to 36.6% of those aged under 50 years (table 1). Older adults were also more likely to be living in a rural location compared to younger adults (P = 0.003). There were no significant differences between age groups for year of initiation or TB status at baseline.

After adjusting for location and sex, age group was not associated with WHO clinical stage at initiation of ART or with the number of HIV-related conditions at initiation. Females were slightly more likely than males to have two or more HIV-related conditions at initiation (odds ratio (OR): 1.17 (95% confidence interval (CI): 1.05 to 1.32)). Those who initiated in semi-urban and rural areas were less likely (OR: 0.61 (95% CI: 0.53 to 0.69)) to have two or more conditions compared to urban patients. Interactions between age and location and between age and sex were tested and were not significant.

Data were available for 8412 individuals for the analysis of treatment outcomes. Of these, 765 (9.1%) died within 5 years of initiation of treatment. Survival rates among those aged 50–59 were not statistically different from those aged 25–49 (P = 0.92) (figure 1). Survival among those aged 60 and older was significantly worse (P = 0.02) than among those 25–49. Those aged 60 and older also had significantly worse survival (P = 0.04) than those aged 50–59. Further analysis revealed that sex was a significant predictor of survival (P<0.0001), with males having worse survival than females (figure 2).

After controlling for sex and WHO clinical stage at initiation, the hazard ratio (HR) for those aged 50–59 compared to those aged 25–49 was 1.00 (95% CI: 0.79 to 1.27; P = 0.99) (table 2). Compared to those aged 25–49 years, those aged 60 and older were at significant increased risk of dying (HR = 1.46 (95% CI: 1.03 to 2.06; P = 0.03)). Controlling for stage and age group, being female reduced the risk of death with a hazard ratio of 0.58 (95% CI: 0.30 to 0.67; P<0.0001). As expected, WHO clinical stage was strongly associated with mortality. After controlling for sex and age group, compared to Stage 1, the hazard ratio for Stage 3 was 3.4 (95% CI: 1.74 to 16.94) and the hazard ratio for Stage 4 was 12.3 (95% CI: 3.93 to 38.32).

Of the 765 who died, 629 (82.2%) died within the first year of ART initiation. The pattern of mortality between the age groups was unchanged with those 50–59 have similar mortality to those aged 25–49 with those 60 and older having higher mortality.

Due to missing outcome data, 2475 (22.7%) of subjects were excluded from survival analyses. The mean age and baseline CD4 of those included in analysis were not meaningfully different from the mean age of those excluded but those excluded were more...
likely to be male and were more likely to have been characterized as WHO Stage 4 on initiation of treatment (table 3). Importantly, the relative differences in sex and WHO Stage between those included and those excluded from survival analyses were largely consistent among those over 50 and among those under 50.

If the excluded patients are included in the survival analysis up to the point when they were classified as missing, the results and significance noted above remained in the same direction and changed only slightly in magnitude. The hazard ratio for those aged 60 and older became 1.52 (95% CI: 1.08 to 2.15; P = 0.0168) while the hazard ratio for those aged 50–59 remained 1.00 compared to those aged 25–49. Using the Kaplan-Meier survival curves, when including those with incomplete outcome data, those 60 and older had significantly worse survival than those 50–59 (P = 0.03).

**Discussion**

Adults aged 50 and older in Zomba District, Malawi, who initiated ART were more likely than younger adults to be male and be receiving treatment at a rural health facility. However, based on WHO clinical stage and number of HIV-related conditions at ART initiation, older adults in this population were no sicker at presentation than younger adults.

We found no difference in mortality on treatment among those aged 50 to 59 years compared to those aged 25 to 49, indicating that people in their fifties respond just as well to treatment as younger people. Survival among those aged 60 and older was reduced; however, this is to be expected due to higher rates of all-cause mortality among older adults. In this study, sex was a much better predictor of survival than age in the Zomba District ART cohort. This study suggests that females are more likely to survive than men.

We found no difference in mortality on treatment among those aged 50 to 59 years compared to those aged 25 to 49, indicating that people in their fifties respond just as well to treatment as younger people. Survival among those aged 60 and older was reduced; however, this is to be expected due to higher rates of all-cause mortality among older adults. In this study, sex was a much better predictor of survival than age in the Zomba District ART cohort. This study suggests that females are more likely to survive than men.

In our study, 9% of those initiated on treatment died over the course of the five years. This level of mortality was higher than was found in Uganda [16] but comparable to data seen in South Africa, Cote d’Ivoire and elsewhere in Malawi [15].

The lack of significant differences in the clinical condition of older adults at initiation of ART is contrary to what has been hypothesized. In Brazil, those aged 60 and older had more AIDS-

### Table 1. Characteristics of patients at initiation of antiretroviral therapy.

|                  | 25–49    | 50–59    | 60+      | P Value (25–49 vs 50+) |
|------------------|----------|----------|----------|------------------------|
| **Sex**          |          |          |          |                        |
| Female           | 6007     | 613      | 169      | <0.0001                |
| Male             | 3462     | 461      | 176      | 0.188                  |
| **WHO Stage / Reason for ART Initiation** |          |          |          |                        |
| Stage 1          | 341      | 29       | 10       | 0.188                  |
| Stage 2          | 3300     | 363      | 121      | 0.188                  |
| Stage 3          | 4281     | 511      | 177      | 0.188                  |
| Stage 4          | 1530     | 167      | 34       | 0.188                  |
| Missing          | 17       | 3        | 3        | 0.188                  |
| **ART Location** |          |          |          |                        |
| Urban            | 4971     | 525      | 154      | 0.003                  |
| Semi Urban       | 1600     | 177      | 71       | 0.003                  |
| Rural            | 2898     | 372      | 120      | 0.003                  |
| **CD4 cell counts at baseline (cells/µl)** |          |          |          |                        |
| less than or equal to 50 | 608 | 39 | 10 |
| between 50 and 99 | 748 | 87 | 28 |
| between 100 and 199 | 1515 | 179 | 55 |
| between 200 and 299 | 1388 | 184 | 68 |
| 300 or over      | 192      | 17       | 8        | 0.001                  |
| Missing          | 5018     | 569      | 176      | 0.001                  |
| Median baseline CD4 | 157 | 171 | 185 | 0.001 |
| **Tuberculosis status at baseline** |          |          |          |                        |
| TB past or present | 1406 | 155 | 52 |
| No TB            | 8063     | 919      | 293      | 0.001                  |
| **Year of ART Initiation** |          |          |          |                        |
| 2009–2010        | 3827     | 415      | 150      | 0.287                  |
| 2007–2008        | 4354     | 525      | 154      | 0.287                  |
| 2005–2006        | 1287     | 134      | 41       | 0.287                  |

*Missing values not included in percentages in categories above. Zomba District by age category 25–49,50–59 and 60 and older who initiated treatment from July 2005 to June 2010. doi:10.1371/journal.pone.0026546.t001
Figure 1. Survival estimates by age. Kaplan-Meier survival estimates by age group for those aged 25 and older who initiated treatment in Zomba District between 1 July 2005 and 30 June 2010. Blue is 25–49 (N = 7297); Red is 50–59 (N = 839); Green is 60+ (N = 276).

doi:10.1371/journal.pone.0026546.g001

Figure 2. Survival estimates by sex. Kaplan-Meier survival estimates by sex for those aged 25 and older who initiated treatment in Zomba District between 1 July 2005 and 30 June 2010. Blue is Male (N = 3057); Red is Female (N = 5355).

doi:10.1371/journal.pone.0026546.g002
defining diseases at diagnosis than those aged 20–39 [8] and a review of developed country studies found that older adults presented later and sicker [6]. However, the recent South African ART among older adults study found that they did not present with more advanced disease than younger individuals [17]. Similar to our findings, the Ugandan study by Bakanda and colleagues also found that older adults were more likely to be male and did not differ in WHO clinical stage at treatment initiation [16].

With regard to treatment outcomes, the Ugandan study found that being aged 50 and older was associated with mortality compared to those 18 to 49 after controlling for other variables [16]. The South African study found that older adults had 32% excess mortality compared to those 25 to 49 [17]. A four site cross-Africa study found that treatment outcomes for over 50s were worse than for younger age groups [15]. Ours is the first study that breaks down the over 50 group into additional age categories for analysis.

Especially for the 50–59 age group, our data confirms what has been seen in non-African studies where older HIV-infected patients responded as well to ART as younger age groups [27–30]. A Brazilian study that compared those aged 20–39 against those aged 60 and older found that, once on ART, mortality between the two groups was similar [8]. A recent case-control study, in which the outcome in patients aged 55 years or older was compared with patients aged 35 years or younger, all treated with ART, concluded that the virological outcome did not differ between groups [31]. The picture is complex however as a number of other studies have found that there is slower recovery of CD4 levels among older adults [12,32]. The eventual higher mortality among older adults in the study was expected and has been seen in other studies [33,34].

Our finding that women on ART are more likely to survive than men has been observed in other studies in Malawi [35] and across Africa [36]. Potential reasons for this sex difference could be that men seek care at a more advanced stage of illness and have poorer levels of adherence.

The strength of the study is its inclusion of program data from an entire district’s ART population including urban and rural sites. However, study limitations include concerns regarding accuracy and consistency that are associated with use of operational data. Because data were extracted from routine monitoring and evaluation indicators, information that might be included in a prospective study is not available, as it is not a part of routine clinical care for ART provision under the Malawi MOH.

### Table 2. Cox proportional hazards models for mortality.

| Variable              | Model with age, sex and WHO Stage at initiation (N = 8390) | Model with Age and Sex (N = 8412) |
|-----------------------|----------------------------------------------------------|-----------------------------------|
|                       | Hazard ratio | 95% confidence limits | P Value | Hazard ratio | 95% confidence limits | P Value |
| Age group             |              |                      |         |              |                      |         |
| 25–49                 | 1.00         | 1.00                 | 0.098   | 1.00         | 1.00                 | 0.216   |
| 50–59                 | 1.00         | 0.79–1.27            | 0.998   | 0.77–1.23    | 0.826                |
| 60+                   | 1.46         | 1.03–2.06            | 0.032   | 1.35         | 0.96–1.91            | 0.086   |
| Sex                   | 0.58         | 0.50–0.67            | <0.0001 | 0.52         | 0.46–0.60            | <0.0001 |
| WHO Stage             |              |                      |         |              |                      |         |
| Stage 1               | 1.00         |                      |         |              |                      |         |
| Stage 2               | 2.38         | 0.76–7.49            | 0.139   |              |                      |         |
| Stage 3               | 5.43         | 1.74–16.94           | 0.004   |              |                      |         |
| Stage 4               | 12.27        | 3.93–38.32           | <0.0001 |              |                      |         |

doi:10.1371/journal.pone.0026546.t002

### Table 3. Comparison of those included in survival analysis and those excluded.

| Total population     | Included in Analysis (N) | Excluded from Analysis (N) |
|----------------------|--------------------------|---------------------------|
| Age (mean)           | 38.3 (8412)              | 38.0 (2475)               |
| Sex (% male)         | 36.3% (3057)             | 42.1% (1042)              |
| WHO Stage 3 and 4 (%)| 61.1% (5122)             | 63.8% (1578)              |
| Baseline CD4 (mean)  | 162.6 (4055)             | 154.6 (1070)              |
| 25 to 49             |                          |                           |
| Age (mean)           | 35.5 (7297)              | 35.5 (2171)               |
| Sex (% male)         | 35.2% (2569)             | 41.1% (893)               |
| WHO Stage 3 and 4 (%)| 60.8% (4425)             | 63.9% (1386)              |
| 50 and older         |                          |                           |
| Age (mean)           | 56.1 (1115)              | 56.0 (304)                |
| Sex (% male)         | 43.8% (488)              | 49.0% (149)               |
| WHO Stage 3 and 4 (%)| 62.9% (697)              | 63.2% (192)               |

doi:10.1371/journal.pone.0026546.t003
public health model and is reflective of resource limitations in that setting. Specifically, high levels of missing baseline CD4 data made usage of that variable difficult.

A further limitation was the approximately 20% loss to follow-up in the dataset. However, the levels of loss to follow-up in this study are comparable to those seen in a review of loss to follow-up across Africa [24]. The exclusion of those lost to follow-up from analysis is likely to have led to underestimation of the absolute number of deaths and mortality rates. However, because the magnitude of differences in characteristics of those included and excluded was similar in the different age groups, the relative risk of death (or hazard ratio) comparing those aged 50 years and over with those aged under 50 was unlikely to be biased.

While some studies have also excluded those lost to follow-up, other studies have used randomization techniques to impute outcome status [16,37]. These imputation techniques make assumptions about which variables are correlated with mortality. For example, Bakanda and colleagues [16] assumed that those with lower CD4 count and those who were older were more likely to die. We did not conduct outcome imputation for those lost to follow-up. Given that age and its relation to mortality was the primary outcome of this study, it was felt that including age in the imputation method would be inappropriate as the method of imputation would be directly related to the primary outcome of interest. Baseline CD4 was also not ideal for use as an imputation variable due to the large number of non-random missing values in our dataset. In the future, greater efforts will be needed to trace those lost to follow-up and examine specific characteristics and determinants of mortality [38,39].

That older adults respond well to ART despite a lack of specifically targeted services is an encouraging sign for ART scale-up. This evidence can be used to combat ageist stigma [40] and to encourage promotion of services among this age group. There have been suggestions there might be higher adherence rates among the elderly – which has been found in developed countries [27,41] – which may be driving the positive treatment response.

With the ageing of the epidemic, HIV has become a complex chronic disease characterised by increasing rates of co-morbid conditions including liver and renal disease, cancers, osteoporosis, neuropsychiatric and cardiovascular diseases [5]. It is well known that older people’s immune systems weaken with age regardless of HIV status leaving older people at greater susceptibility to a range of conditions [42,43] – but this has not been specifically studied in Africa among those on ART. The ageing of the epidemic has implications on service delivery with a growing need for integrated diagnostic and treatment services for HIV and non-communicable diseases.

Older adults have been largely neglected by the global HIV response but there are encouraging signs that those aged 50 and older are starting to be seen by the HIV community as productive, fully active contributors, care givers, and educators, whose susceptibility to HIV needs to be integrated into the core of the response to the epidemic.

Acknowledgments

We are grateful to the ART providers at Zomba Central Hospital and in Zomba District for their dedication to patient care. We are grateful to the Zomba Central Hospital, Zomba District Health Office Management and the MOH of Malawi for the collaboration and encouragement in trying to implement HIV-related activities. We would also like to thank the Dignitas International Data Management Team for their meticulous work with data collection and support.

Author Contributions

Conceived and designed the experiments: MVL MS AC. Performed the experiments: MS AC. Analyzed the data: JN RGC. Contributed reagents/materials/analysis tools: JN AM RGC MVL. Wrote the paper: JN MVL AM RGC.

Reference

1. Negin J, Cumming RG (2010) HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data. Bull World Health Organ 88: 847–853.
2. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2010) Global Report: UNAIDS report on the global AIDS epidemic 2010. Geneva:UNAIDS.
3. Mills EJ, Rammohan A, Awofose N (2010) Ageing faster with AIDS in Africa. Lancet 377: 1131–1133.
4. Schmid GP, Williams BG, Garcia-Calleja JM, Miller C, Sagar E, et al. (2009) Under explored story of HIV and ageing. Bull World Health Organ 87: 162–162.
5. Justice AC (2010) HIV and ageing: time for a new paradigm. Curr HIV/AIDS Rep 7: 69–76.
6. Martin CP, Fain MJ, Klots SA (2008) The older HIV-positive adult: a critical review of the medical literature. Am J Med 121(12): 1032–7.
7. Smith RD, Delpech VC, Brown AE, Rice BD (2010) HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS 24: 2109–2113.
8. Lacerda HR, Kimer D (2008) Mortality of the elderly is still exceedingly high at diagnosis of AIDS despite favourable outcomes after highly active antiretroviral therapy in Recife, Brazil. Int J STD AIDS 19: 450–4.
9. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR (1996) Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. UK Haemophilia Centre Directors’ Organisation. Lancet 347(9015): 1573–9.
10. Collaborative Group on AIDS Incubation and HIV Survival (2000) Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 355(9210): 1131–7.
11. Nguyen N, Holodniy M (2008) HIV infection in the elderly. Clin Infect Aging 35(2): 453–72.
12. Goetx MB, Roscadin WN, Dorothy W, Alassoepoos S (2001) Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy. AIDS 15: 1576–9.
13. Bonnet F, Thebaud R, Chene G, Neau D, Pellegrin JL, et al. (2005) Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med 6(3): 196-205.
14. Brinkhof MW, Boulle A, Weigel R, Mesou E, Mathers C, et al. (2009) Mortality of HIV-Infected Patients Starting Antiretroviral Therapy in Sub-Saharan Africa: Comparison with HIV-Related Mortality. PLoS Med 6(4): e1000086.
15. May M, Boulle A, Phiri S, Mesou E, Myer L, et al. (2010) Progression of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 375: 449–457.
16. Bakanda C, Birungi J, Mwesigwa R, Ford N, Cooper CL, et al. (2011) Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy. AIDS 25(5): 701–5.
17. Mutevedzi PC, Leselfi RJ, Rodger AJ, Newell ML (2011) Association of age with mortality and virological and immunological response to antiretroviral therapy, in rural South African adults. PLoS One 6(7): e21795.
18. Negin J, Nemer B, Cumming R, Lekera E, BenAmor Y, et al. HIV attitudes, awareness and testing among older adults in Africa. AIDS and Behavior. 8 July 2011 Epub ahead of print.
19. Kimokoti RW, Hamer DH (2008) Nutrition, health, and aging in sub-Saharan Africa. Nutr Rev 66(11): 611–23.
20. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat (2010) World Population Prospects: The 2010 Revision. Available: http://esa.un.org/unpd/wpp/index.htm.
21. Chan AK, Matsyu G, Jahn A, Schouten E, Aroha P, et al. (2010) Outcome assessment of decentralization of antiretroviral therapy provision in a rural district of Malawi using an integrated primary care model. Trop Med Int Health 15 (suppl 1): 90–97.
22. United Nations (2010) The Millennium Development Goals Report 2010. New York.
23. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2009) Monitoring the Declaration of Commitment on HIV/AIDS: guidelines on construction of core indicators : 2010 reporting. Geneva.
24. Brinkhof MW, Pujades-Rodriguez M, Egger M (2009) Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 4(6): e5790.
25. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, et al. (2007) True screenplay for AIDS epidemic. AIDS 2109–2115.
26. United Nations (2010) The Millennium Development Goals Report 2010. New York.
26. Weigel R, Hochgesang M, Brinkhof MW, Hosseinipour MC, Boxshall M, et al. (2011) Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe, Malawi. BMC Infect Dis 11: 31.

27. Wellons MF, Edwards LJ, Bartlett JA, Heald AE, Schmader KE (2002) HIV Infection: Treatment Outcomes in Older and Younger Adults. J Am Geriatr Soc 50: 603–607.

28. Perez JL, Moore RD (2003) Greater impact of HAART on survival in people older than fifty with HIV infection compared to younger people in an urban observational cohort. Clin Infect Dis 36: 212–28.

29. Grimes RM, Otimiano ME, Rodriguez-Barradas M, Lai D (2002) Clinical experience with human immunodeficiency virus infected older patients in the era of effective antiretroviral therapy. Clin Infect Dis 34: 1530–3.

30. Knobel H, Guelar A, Valdecillo G, Carmona A, Gonzalez A, et al. (2001) Response to highly active therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS 15: 1591–3.

31. Manfredi R, Chiodo F (2000) A case–control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. AIDS 14: 1475–1477.

32. Viard JP, Mocroft A, Chaisi A, Kirk O, Roque B, et al. (2001) Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 183: 1290–1294.

33. Gebo KA (2009) HIV infection in older people. BMJ 338: b1460.

34. COHERE (2008) Response to combination antiretroviral therapy: variation by age. AIDS 22: 1463–73.

35. Chen SC, Yu JK, Harries AD, Bong CN, Kolola-Deimadzi R, et al. (2008) Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health 13(4): 513–9.

36. Kipp W, Alibhai A, Saunders LD, Senahivelvan A, Kaler A, et al. (2010) Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda. AIDS Care 22(3): 271–8.

37. Egger M, Spycher BD, Siste J, Weigel R, Geng EH, et al. (2011) Correcting Mortality for Loss to Follow-Up: A Nomogram Applied to Antiretroviral Treatment Programmes in Sub-Saharan Africa. PLoS Med 8(1): e1000390. doi:10.1371/journal.pmed.1000390.

38. Geng EH, Glidden DV, Emenyu N, Musinguzi N, Bwana MB, et al. (2010) Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. Trop Med Int Health 15 Suppl 1: 63–9.

39. Tweya H, Gareta D, Chagwera F, Ben-Smith A, Mwenyemasi J, et al. (2010) Early active follow-up of patients on antiretroviral therapy (ART) who are lost to follow-up the ‘Back-to-Care’ project in Lilongwe, Malawi. Trop Med Int Health 15 Suppl 1: 82–9.

40. Kasunda A (2010) Leave drugs for young ones, elders told. Nation on Sunday [Malawi]. 6 November 2010. Available: http://www.nationmw.net/index.php?option=com_content&view=article&id=8963:leave-drugs-for-young-ones-elders-told&catid=119:national-news&Itemid=125 2010.

41. Ettenhofer ML, Hinkin CH, Castellon SA, Durvasula R, Ullman J, et al. (2009) Aging, neurocognition, and medication adherence in HIV infection. Am J Geriatr Psychiatry 17(4): 291–90.

42. Castle SC (2000) Clinical relevance of age-related immune dysfunction. Clin Infect Dis 31(2): 578–85.

43. Weng NP (2006) Aging of the immune system: how much can the adaptive immune system adapt? Immunity 24(3): 495–9.